12 MONTH COMPARISON OF SALMETEROL AND SALBUTAMOL AS DRY POWDER FORMULATIONS IN ASTHMATIC-PATIENTS

被引:85
作者
LUNDBACK, B
RAWLINSON, DW
PALMER, JBD
机构
[1] GLAXO GRP RES LTD,DEPT RESP MED,GREENFORD UB6 0HE,MIDDX,ENGLAND
[2] NATL INST OCCUPAT HLTH,DIV MED,UMEA,SWEDEN
关键词
D O I
10.1136/thx.48.2.148
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Salmeterol is a potent selective beta2 agonist that has been shown to have a duration of action in excess of 12 hour s. In this study salmeterol and salbutamol were compared over a three month period with a further extension of nine months. Methods Three hundred and eighty eight patients with mild to moderate reversible airways obstruction (forced expiratory volume in one second (FEV1) >50% predicted) were randomised to receive salmeterol (50 mug) twice daily or salbutamol (400 mug) four times daily, both by dry powder, in a double blind parallel group study. During the first three months detailed assessment of efficacy was made with recording of morning and evening peak expiratory flow rates (PEF), asthma symptoms, and bronchodilator use when necessary for the relief of symptoms. Patients continued in the study for a further nine months with the salbutamol dose reduced to 400 mug twice daily. Lung function was measured at the clinic and safety data were collected during this period. Results Salmeterol produced a significantly higher mean morning PEF (mean difference compared with salbutamol 21 (95% CI 12-31) 1/min), and a significant reduction in mean diurnal variation in PEF (from 30 1/min at baseline to 11 1/min during salmeterol compared with 34 1/min at baseline to 32 1/min during salbutamol treatment). Salmeterol also reduced day and night symptoms and use of rescue bronchodilator. FEV1 increased with both salmeterol and salbutamol treatment over the 12 month treatment period. For both treatments the number of patients reporting exacerbations of asthma and the frequency of these exacerbations remained constant during the study. Thirty six patients in the salmeterol and 49 in the salbutamol group withdrew during the 12 months of the study. Conclusions In this study salmeterol (50 mug twice daily) was more effective than salbutamol (400 mug four times daily) in the control of asthma over three months, and more effective than salbutamol (400 mug twice daily) over a further nine months. Neither salmeterol nor salbutamol was associated with any worsening of control of asthma.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 18 条
[1]   DURATION OF PROTECTION BY INHALED SALMETEROL IN EXERCISE-INDUCED ASTHMA [J].
ANDERSON, SD ;
RODWELL, LT ;
DUTOIT, J ;
YOUNG, IH .
CHEST, 1991, 100 (05) :1254-1260
[2]   SALMETEROL, A NOVEL, LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST - CHARACTERIZATION OF PHARMACOLOGICAL ACTIVITY INVITRO AND INVIVO [J].
BALL, DI ;
BRITTAIN, RT ;
COLEMAN, RA ;
DENYER, LH ;
JACK, D ;
JOHNSON, M ;
LUNTS, LHC ;
NIALS, AT ;
SHELDRICK, KE ;
SKIDMORE, IF .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (03) :665-671
[3]  
BRITTON MG, 1992, EUR RESPIR J, V5, P1062
[4]   CHOICE OF DRUG-TREATMENT IN ASTHMA [J].
CLARK, TJH .
PHARMACOLOGY & THERAPEUTICS, 1982, 17 (02) :221-228
[5]  
DAHL R, 1991, EUR RESPIR J, V4, P1178
[6]   A SINGLE-DOSE COMPARISON OF INHALED ALBUTEROL AND 2 FORMULATIONS OF SALMETEROL ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS [J].
GONGORA, HC ;
WISNIEWSKI, AFZ ;
TATTERSFIELD, AE .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03) :626-629
[7]  
LARSSON S, 1977, AM REV RESPIR DIS, V116, P861
[8]   SALMETEROL, A NEW INHALED BETA2-ADRENERGIC AGONIST, HAS A LONGER BLOCKING EFFECT THAN ALBUTEROL ON HYPERVENTILATION-INDUCED BRONCHOCONSTRICTION [J].
MALO, JL ;
GHEZZO, H ;
TRUDEAU, C ;
LARCHEVEQUE, J ;
CARTIER, A .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 89 (02) :567-574
[9]  
MATHIEU M, 1992, EUR J CLIN PHARMACOL, V42, P435
[10]   AEROSOLIZED BRONCHODILATORS AND STEROIDS IN THE TREATMENT OF AIRWAY-OBSTRUCTION IN ADULTS [J].
MCFADDEN, ER .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1980, 122 (05) :89-96